Stock Ratings / Health Care / VYGR / options

LENZ (44) BDTX (59) ENGN (34) OTLK (38) ⌘ Pro Terminal →

Voyager Therapeutics Inc. (VYGR) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is VYGR trading relative to its 50-day, 200-day, and 52-week technical levels?

VYGR last traded at $1.72 (-2.27% on volume of 878,836 shares), positioning the stock -35.82% below its 50-day simple moving average ($2.68) and -50.14% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.68 to $5.48, VYGR sits at the 1.1% percentile with a 14-day RSI of 31.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.51 to $1.93).

Q: What is VYGR's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for VYGR.

$1.72 -2.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.71

Voyager Therapeutics Inc. (VYGR) carries a Roarable Rating of E (Strong Sell) with 15/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (15/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $108.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VYGR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VYGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Voyager Therapeutics Inc. (NASDAQ: VYGR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 15/100 at a spot price of $1.72 (-2.27% 1D, market cap $108.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VYGR ranks #1015 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VYGR compare to LENZ and BDTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VYGR carries a Roarable E (15/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LENZ (LENZ Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M) and BDTX (Black Diamond Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M). Among the 5-stock peer group, VYGR leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VYGR?

▼

Per VYGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001640266), Voyager Therapeutics Inc. generated $40.4M in revenue (-49.5% YoY), -$119.7M in net income, and -$135.1M in free cash flow against $252.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.71 (-0.60%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (15/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-19.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VYGR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (15/100 Composite)

🔍 WHY VYGR SCORES 15/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+5/20 pts (33% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.8 (OVERSOLD (<32))

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.27-9.7% Next Q

Q2 (-2Q)

Grade E$2.05-14.6% Next Q

Q3 (-1Q)

Grade E$1.75-1.7% Next Q

Current

Grade E$1.72-12.9% Hist 90D α

Trajectory: E (23) → E (15)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VYGR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VYGR currently carries a cautious 15/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.68) and Max Pain ($1.81) forces dealer call-delta covering toward $5.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VYGR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VYGR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 18%NO 82%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (VYGR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for VYGR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VYGR)

✓Walkthrough of VYGR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VYGR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.67%▼ SUPPORT BREAKDOWN

2026-11-02O $1.84H $1.84L $1.72C $1.72VOL 659.9K

RES: $3.11SUP: $2.24SMA50: $2.68SMA200: $3.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VYGR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VYGR Butterfly Map → + Track VYGR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -49.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VYGR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VYGR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VYGR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VYGR)

Health Care Rank #1015 of 1016 ⚔️ LENZ vs VYGR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VYGR vs. LENZ, BDTX, ENGN, OTLK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Voyager Therapeutics Inc. (VYGR) ranks #1015 by composite RQD confidence (15/100, grade E) and #648 by equity capitalization ($108.4M). Within this direct 5-issuer industry benchmark cohort, VYGR leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with VYGR at 15/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VYGR ACTIVE Voyager Therapeutics Inc.	E	15/100	—	—	-35.0%	-2.27%	$108.4M	Benchmark Subject
LENZ LENZ Therapeutics Inc.	D	44/100	—	96.0%	-27.8%	-12.61%	$109.7M	/lenz-vs-vygr →
BDTX Black Diamond Therapeutics Inc.	C-	59/100	—	—	10.8%	-4.30%	$106.9M	/bdtx-vs-vygr →
ENGN enGene Therapeutics Inc.	E	34/100	—	—	-35.0%	0.00%	$102.5M	/engn-vs-vygr →
OTLK Outlook Therapeutics Inc.	D-	38/100	—	4.0%	-35.0%	-5.15%	$120.1M	/otlk-vs-vygr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001640266

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Voyager Therapeutics Inc. (VYGR) reported GAAP revenue of $40.4M (-49.5% vs. FY2024 revenue of $80.0M , and -83.9% cumulative change since FY2023) , GAAP net income of -$119.7M, operating cash flow of -$132.5M, and free cash flow of -$135.1M (-617.2% YoY). On the balance sheet, VYGR closed FY2025 with $252.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$40.4M	-$119.7M	-$132.5M	-$135.1M	$252.3M	—
FY2024 (FY)	2024-12-31	$80.0M	-$65.0M	-$15.3M	-$18.8M	$393.1M	—
FY2023 (FY)	2023-12-31	$250.0M	$132.3M	$77.9M	$77.9M	—	—

3. VYGR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VYGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VYGR compare to LENZ and BDTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VYGR?

Where is VYGR trading relative to its 50-day, 200-day, and 52-week technical levels?

VYGR last traded at $1.72 (-2.27% on volume of 878,836 shares), positioning the stock -35.82% below its 50-day simple moving average ($2.68) and -50.14% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.68 to $5.48, VYGR sits at the 1.1% percentile with a 14-day RSI of 31.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.51 to $1.93).

VYGR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is VYGR's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for VYGR.

Direct Sub-Reports: VYGR RQD Cockpit VYGR 12M Forecast VYGR Earnings & Move VYGR Dividends & DRIP VYGR Insiders & 13F VYGR Whale Options VYGR Profit Sankey VYGR News & Why

ROARABLE RATING BRIEF • RQD 15/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VYGR — Voyager Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, VYGR scores 15 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 0 / 20, reflecting a ROIC of -35% and an FCF yield of 0%; for a prospective investor, this means the business is not currently generating returns on capital or free cash flow to support valuation. The Whale 13F Flow pillar scores 3 / 20 for institutional accumulation and options positioning, indicating weak institutional support. The Insider Conviction pillar scores 3 / 20 based on SEC Form 4 and Congressional PTR cluster flow, indicating limited insider-side confidence signals in the source data. The Macro Regime Fit pillar scores 5 / 20 with a Beta of 1.0 and sector sensitivity, meaning the stock tracks broad market movement without a clear defensive offset. The Forensic Balance Sheet pillar scores 4 / 20, driven by an Altman Z-Score of 0.2, a Piotroski F-Score of 1/9, and a Debt/Equity ratio of 0.5; these forensic readings point to elevated financial distress risk. Taken together, the rating frames the stock as high-risk on current source data, with the primary upside case depending on future operational improvement that the provided figures do not yet show.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$40.4M	$-131.8M	$-119.7M	N/A	$-135.1M	$65.3M	N/A
FY 2024	$80.0M	$-83.3M	$-65.0M	N/A	$-18.8M	$71.4M	N/A
FY 2023	$250.0M	$122.0M	$132.3M	N/A	$77.9M	N/A	N/A

Per the market data section, the operating margin and net margin are each -60%, and the gross margin is 0%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 1/9, both consistent with significant financial stress, and the Debt/Equity ratio is 0.5. The sequence of operating losses from FY 2023 through FY 2025 and the FY 2025 free cash flow of $-135.1M against cash of $65.3M are notable in the source figures. Debt values are Not available in source data for the reported periods.

Open Questions

What are VYGR's specific products, partnerships, and revenue sources that explain the decline from $250.0M in FY 2023 to $40.4M in FY 2025?
What is the company's cash runway given FY 2025 free cash flow of $-135.1M against reported cash of $65.3M?
What are the debt balances and maturities for the reported periods, since debt is N/A in the financials?
What are the timing and outcomes of the referenced Alzheimer's gene therapy safety data and PET imaging readouts?
What is the analyst consensus, price target range, and institutional or insider ownership, since those sections are empty in the source data?

VYGR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Voyager Therapeutics Inc. (VYGR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VYGR Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 4h ago

Voyager Therapeutics, Inc. Estimates – NASDAQ:VYGR

TradingView report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 7h ago

Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More (NASDAQ:VYGR)

Seeking Alpha report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 10h ago

H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)

The Globe and Mail report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 13h ago

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky

Simply Wall St report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 16h ago

Voyager’s CEO handoff is expected after initial safety data from an Alzheimer’s gene therapy trial.

Stock Titan report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 19h ago

Voyager Therapeutics (NasdaqGS:VYGR) Stock Forecast & Analyst Predictions

Simply Wall St report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 22h ago

Voyager Therapeutics (VYGR) Slips 7.35% to $2.27 as Selling Pressure Builds - Social Sentiment

https://www.siam.in/ report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Voyager Therapeutics (VYGR) Rises 3.38% to $2.45, Testing the Middle of Its Recent Range - Combination Correction

https://www.dars.gov.et/ report covering Voyager Therapeutics Inc. (VYGR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VYGR Bull vs. Bear Conversation Board — What's Your Call at $1.72?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VYGR 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.55 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is VYGR (E • RQD 15/100) a Buy at $1.76?

Welcome to the VYGR (Voyager Therapeutics Inc.) Roar Pit. Current RQD Composite is 15/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.37 (-22.2%)

Spot @ $1.76

Pump the brakes on VYGR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on VYGR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Voyager Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.20 (+25.0%)

Spot @ $1.76

VYGR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on VYGR, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.76 (52-wk range $1.68 - $5.48), any beat on forward guidance forces shorts and underweight funds to chase.